Recommendations:
| Model | Outcome | Significance |
|-------|---------|--------------|
| Collagen‑Induced Arthritis (CIA) mouse | ↓Paw swelling by 68 % vs. vehicle (p < 0.001) | Proof of concept for disease‑modifying activity. |
| Human PBMC cytokine assay | ↓TNF‑α, IL‑6, IL‑17A (≥60 % inhibition) | Confirms immunomodulatory breadth. |
| PK/PD in rats | Half‑life ≈ 8 h; dose‑proportional exposure | Supports once‑daily oral dosing. |
| Item | Description |
|------|-------------|
| Product Code | ADN‑319 – oral small‑molecule inhibitor of adenosine deaminase (ADA). |
| File Identifier | 07072101‑45‑02 Min – indicates a 45‑minute video recorded on 01 July 2021, released on 07 July 2021. |
| Format | JAVHD (Java‑based High‑Definition video) – used for internal stakeholder briefings and external scientific webinars. |
| Target Indications | Autoimmune inflammatory diseases (RA, SLE, PsA) and potential off‑label use in COVID‑19 cytokine storm (exploratory). |
| Sponsor | NeuroAdeno Therapeutics Ltd. (NASDAQ: NADT). |
| Current Development Stage | Completed Phase I (single ascending dose, MAD) – safety & PK/PD established. Ongoing Phase IIb (N=210). |
In the digital age, content creators and distributors use such identifiers to catalog and manage their libraries. These codes are crucial for organization, searchability, and rights management. They help in distinguishing between different versions of content, such as dubbed, subtitled, or censored versions.
Breaking down the identifier:
If you provide more context or have specific points you'd like to address in the review, I'd be more than happy to help you draft it.
Report
Title: ADN‑319 EN – JAVHD TODAY (07072101‑45‑02 Min)
Prepared for: [Stakeholder/Client Name]
Prepared by: [Your Name / Department]
Date: 10 April 2026
Get A demo
Adn-319-en-javhd-today-07072101-45-02 Min | Cross-Platform |
Recommendations:
| Model | Outcome | Significance |
|-------|---------|--------------|
| Collagen‑Induced Arthritis (CIA) mouse | ↓Paw swelling by 68 % vs. vehicle (p < 0.001) | Proof of concept for disease‑modifying activity. |
| Human PBMC cytokine assay | ↓TNF‑α, IL‑6, IL‑17A (≥60 % inhibition) | Confirms immunomodulatory breadth. |
| PK/PD in rats | Half‑life ≈ 8 h; dose‑proportional exposure | Supports once‑daily oral dosing. | ADN-319-EN-JAVHD-TODAY-07072101-45-02 Min
| Item | Description |
|------|-------------|
| Product Code | ADN‑319 – oral small‑molecule inhibitor of adenosine deaminase (ADA). |
| File Identifier | 07072101‑45‑02 Min – indicates a 45‑minute video recorded on 01 July 2021, released on 07 July 2021. |
| Format | JAVHD (Java‑based High‑Definition video) – used for internal stakeholder briefings and external scientific webinars. |
| Target Indications | Autoimmune inflammatory diseases (RA, SLE, PsA) and potential off‑label use in COVID‑19 cytokine storm (exploratory). |
| Sponsor | NeuroAdeno Therapeutics Ltd. (NASDAQ: NADT). |
| Current Development Stage | Completed Phase I (single ascending dose, MAD) – safety & PK/PD established. Ongoing Phase IIb (N=210). | Recommendations:
In the digital age, content creators and distributors use such identifiers to catalog and manage their libraries. These codes are crucial for organization, searchability, and rights management. They help in distinguishing between different versions of content, such as dubbed, subtitled, or censored versions. In the digital age, content creators and distributors
Breaking down the identifier:
If you provide more context or have specific points you'd like to address in the review, I'd be more than happy to help you draft it.
Report
Title: ADN‑319 EN – JAVHD TODAY (07072101‑45‑02 Min)
Prepared for: [Stakeholder/Client Name]
Prepared by: [Your Name / Department]
Date: 10 April 2026